High expression of PSMA in prostate cancer makes it an attractive target for imaging and therapy. The left image shows a Prostascint scan (indium-111-capromab, an anti-PSMA antibody) in a patient with metastatic prostate cancer (black arrow). The FDA recently approved 2 PET radiopharmaceuticals that bind the extracellular domain of PSMA (Ga-68-gozetotide and F-18-piflufolostat). The right image shows an F-18-piflufolostat scan. The superior signal-to-noise and resolution of PET allow for detection of the tiny metastatic nodes seen in the pelvis.
Image credit
Left: Bhargava et al. Am. Jour. Nucl. Med. Mol. Imag. 2012.
Right: Dr. Thomas Anderson











